Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00460811 · ClinicalTrials.gov registry record · Phase 2
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
A Phase 2 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
NCT00460811 is a Phase 2 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 420 participants.
The verdict
NCT00460811, a Phase 2 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
Interventions
- DRUG Matching placebo
- DRUG Linaclotide Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00460811
The ClinicalTrials.gov registry entry for NCT00460811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching placebo is the first listed.
NCT00460811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00460811 about?
NCT00460811 is a clinical study titled "Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)". The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
What is the current status of trial NCT00460811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2007-04. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00460811?
The interventions under investigation include: Matching placebo (DRUG), Linaclotide Acetate (DRUG).
Who is sponsoring clinical trial NCT00460811?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.